Filing Flows › Integra Lifesciences Holdings (IART) › Q2 2025
Integra Lifesciences Holdings (IART) Q2 2025 earnings results (second quarter 2025)
10-Q filed Jul 31, 2025
Integra Lifesciences Holdings (IART) reported revenue of $416M for the second quarter 2025 (Q2 2025), -0.6% from a year earlier and +9% from the quarter before. Operating margin was -123.4%, net loss $484M (116.5% of revenue).
Integra Lifesciences Holdings, Q2 2025: revenue $416M (-0.6% year over year), operating margin -123.4%, net loss $484M, operating cash flow $8.9M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $416M | +9% | -0.6% |
| Operating profit | −$513M | — | — |
| Net earnings | −$484M | — | — |
| Operating cash flow | $8.9M | — | -78% |
What changed
Revenue was $415.6M in Q2 2025, down 1% year over year and up 9% from the previous quarter. Codman Specialty Surgical was the largest line at 73% of revenue. Tissue Technologies lost $4.8M year over year (down 4%), 185% of the total change.
Operating costs exceeded revenue by $512.7M, an operating margin of -123.4%. Total costs grew 120% against a revenue fall of 1%. The fastest-growing cost line was Other operating costs (+13796%). The quarter ended with a net loss of $484.1M, wider than the previous quarter's $25.3M loss.
Operating cash flow was $8.9M (down 78% year over year). Non-cash charges added back $5.3M of share-based compensation. Working capital and other items added $487.7M. Capital expenditures of $20.1M exceeded it, leaving free cash flow of −$11.2M.
Questions
What was Integra Lifesciences Holdings' revenue in the second quarter 2025?
Integra Lifesciences Holdings (IART) reported revenue of $416M for the second quarter 2025 (Q2 2025), -0.6% from a year earlier and +9% from the quarter before.
Was Integra Lifesciences Holdings profitable in the second quarter 2025?
Operating loss was $513M (-123.4% of revenue) and net loss $484M.